Insights On Enterprise Solutions

  1. Periodic Counter Current Chromatography: A Step Toward Continuous DSP 12/19/2025

    PCC boosts Protein A capture efficiency, cuts resin costs, increases productivity, and enables continuous downstream processing without sacrificing quality or compliance.

     

  2. Enriching Sterile Fill/Finish Services With A Patient-Centric Approach 12/18/2025

    Through early collaboration and advanced aseptic technology, organizations can overcome complex formulation challenges to ensure safe, effective treatments reach patients more efficiently than before.

  3. Discussing Qualities Of A CDMO Redefining Innovation 12/18/2025

    Ensuring precision in fill/finish for large-volume devices is critical for performance. Discover the essential traits that redefine innovation and support patient-centric manufacturing solutions.

  4. A Look At The Evolution Of Aseptic Manufacturing 12/18/2025

    The transition toward complex biologics and patient-centric delivery is redefining sterile manufacturing. Success now depends on adopting flexible production strategies and advanced technologies.

  5. Agile Adaptation In mRNA-LNP Manufacturing: A CDMO's Response 12/17/2025

    Find flexible scale-up from lab through commercial manufacturing, leveraging expertise. Gain technical insights for scalable, efficient development for advancing mRNA, saRNA, or circular RNA programs.

  6. Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D. 12/16/2025

    In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to talk about the potential advancements that can be made in biomanufacturing by combining AI with operations research (OR).

  7. Tech Transfer Answers: How To Successfully Onshore A Mid-Phase Project 12/16/2025

    Onshoring biomanufacturing operations is an increasingly common decision. While a mid-phase tech transfer from international to domestic CDMO can be complex, the right partner can ensure success.

  8. TESSA® Platform Optimization For AAV Manufacture Efficiency 12/15/2025

    Optimized TESSA® platform boosts AAV yields up to 30-fold, improves capsid quality, and reduces costs by 85%, enabling scalable, contamination-free manufacturing for advanced gene therapy applications.

  9. Silencing Lentiviral Cargo For Cell Therapy 12/15/2025

    Silencing lentiviral cargo genes boosts vector yield, enhances cell viability, and reduces impurities, enabling scalable, cost-effective manufacturing for complex gene therapies.

  10. Advancing Scalable Vector Production For AAV-Based Treatments 12/15/2025

    TESSA® enables scalable, high-yield AAV manufacturing with minimal contamination, delivering >10¹⁷ genome copies per 200L run and supporting efficient, GMP-compliant production for diverse serotypes.